SequelSEC

Dare Bioscience, Inc. DARE

Pharmaceutical Preparations · CIK 0001401914 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.03M
Fiscal year ended 2025-12-31
Operating income
-$13.55M
Fiscal year ended 2025-12-31
Free cash flow
-$10.27M
Fiscal year ended 2025-12-31

Dare Bioscience, Inc. (DARE) reported revenue of $1.03M and net income of -$13.40M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Dare Bioscience, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Dare Bioscience, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312016-12-312014-12-31
Revenue$1.03M$9.78K$2.81M$10.00M$0$766.00K$80.00K
Cost of revenue$295.80K$0UnavailableUnavailableUnavailableUnavailableUnavailable
Gross profit$734.39K$9.78KUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$13.55M-$23.45M-$30.94M-$31.39M-$39.07M-$630.59KUnavailable
Net income-$13.40M-$4.05M-$30.16M-$30.95M-$38.70M-$672.69K-$23.34M
Research & development$5.52M$14.31M$21.54M$30.04M$30.62M$72.67K$11.77M
Weighted-average diluted sharesshares 11.18Mshares 8.50Mshares 7.28Mshares 84.57Mshares 61.15Mshares 835.00KUnavailable
Pretax income-$13.54M-$4.05M-$30.16M-$30.95M-$38.70M-$673.00KUnavailable
Income tax expense$0$0$0$0$0UnavailableUnavailable
Diluted EPS$-1.20$-0.48$-4.15$-0.37$-0.63UnavailableUnavailable
Selling, general & administrative$8.76M$9.16MUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailable$9.16M$12.11M$11.24M$8.35M$157.92K$8.59M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Dare Bioscience, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312016-12-312014-12-31
Cash & equivalents$24.71M$15.70M$10.48M$34.67M$51.67M$44.61K$51.17M
Total assets$32.47M$22.10M$21.28M$43.83M$55.81M$44.61K$53.39M
Current assets$27.06M$18.45M$17.54M$43.04M$55.30M$44.61K$52.84M
Total liabilities$29.63M$28.11M$26.33M$32.71M$17.05M$755.24KUnavailable
Current liabilities$23.69M$21.61M$20.48M$31.62M$16.05M$755.24K$8.06M
Total equity incl. NCI$2.84M-$6.01M-$5.05M$11.11M$38.75M-$710.62K$45.32M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable$0$823.00KUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.20M$1.46M$3.39M$2.03M$2.10M$1.45M$1.26M

Cash flow

Dare Bioscience, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312016-12-312014-12-31
Operating cash flow-$9.89M$5.47M-$38.86M-$18.09M-$28.76MUnavailableUnavailable
Capital expenditures$385.28K$573.05K$629.43K$63.07K$14.52K$535.00K$225.00K
Investing cash flow-$385.28K-$573.05K-$629.43K-$63.07K-$14.52KUnavailableUnavailable
Financing cash flow$19.28M$354.52K$15.64M$1.34M$75.85MUnavailableUnavailable
Net change in cash$9.01M$5.19M-$23.86M-$17.00M$47.00M-$174.80K$45.69M
Stock-based compensation$1.50M$2.20M$2.53M$2.16M$1.60M$9.01K$885.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.63M$42.32KUnavailableUnavailableUnavailable$261.00K$126.00K

Derived

Dare Bioscience, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312016-12-312014-12-31
Free cash flow-$10.27M$4.90M-$39.49M-$18.15M-$28.78MUnavailableUnavailable
Gross margin71.3%100.0%UnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-1315.5%-239692.2%-1101.9%-313.9%UnavailableUnavailableUnavailable
FCF margin-997.0%50087.0%-1406.3%-181.5%UnavailableUnavailableUnavailable
SBC / revenue145.3%22519.0%90.1%21.6%UnavailableUnavailable1106.2%
Current ratio1.14x0.85x0.86x1.36x3.44x0.06x6.55x
Revenue YoY growth10429.4%-99.7%-71.9%UnavailableUnavailableUnavailableUnavailable
Net margin-1300.7%-41430.9%-1074.2%-309.5%UnavailableUnavailable-29177.5%
R&D / revenue536.1%146210.2%767.1%300.4%UnavailableUnavailable14715.0%
CapEx / revenue37.4%5857.0%22.4%0.6%Unavailable69.8%281.2%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DARE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.